ACU

Business Context and Reporting Period

Company: Acme United Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1995
Business Overview: A multinational corporation operating in two segments: Consumer Products (scissors, shears, rulers, knives, first aid kits) and Medical Products (disposable instruments, procedure trays, wound care). Operations are located in the U.S., Canada, England, and Germany.

Key Financial Metrics

Margins: Gross margins declined in both segments. Consumer margins fell from 24% to 21%; Medical margins fell from 38% to 36%.

Material Changes vs. Prior Period

• Significant Loss: The company swung from a net income of $123,000 in 1994 to a net loss of $8.7 million in 1995.
• Restructuring and Asset Charges: A total charge of $6.7 million was recorded, comprising $3.1 million for restructuring (lease terminations, employee terminations) and $3.6 million for asset revaluations.
• Inventory Write-downs: An inventory valuation loss of $3.4 million was taken to support a company-wide inventory reduction plan aimed at converting inventory to cash.
• Segment Performance:
  • Consumer: Sales increased slightly in the U.S. but declined in foreign operations (Europe). Operating loss was $4.3 million.
  • Medical: Sales were flat at $16.3 million. Operating profit was $394,000, impacted by write-offs of the "Bubble and Board" IV therapy line ($200,000) and other asset revaluations ($1.2 million).
• Liquidity: Working capital decreased by $5.1 million, and the long-term debt-to-equity ratio worsened from 0.80 to 1.57 due to the reduction in stockholders' equity.

Guidance, Outlook, and Management Commentary

Turnaround Strategy: Management has initiated a comprehensive restructuring plan to restore profitability by 1997. Key actions include:

• Manufacturing Consolidation: Moving U.S. consumer manufacturing from Bridgeport, CT, to Fremont, NC, to save approximately $700,000 annually (fully realized in 1997).
• Cost Reduction: A program targeting over $1 million in annual savings through salary reductions, benefit plan revisions, and lower administrative expenses.
• Inventory Management: Aggressive inventory reduction to generate cash, with an expectation to recover $2.8 million by the end of 1996.
• European Operations: Plans to reduce expenses and eliminate selected manufacturing operations in Germany and England to decrease losses.

Outlook: Management forecasts modest sales growth for 1996. The company expects to be in a solid position for future growth and profitability by 1997 if the current course is maintained.

Risks and Contingencies:

• Covenant Violations: The company was in violation of various covenants on its revolving credit line as of December 31, 1995, though these were waived in March 1996.
• Market Competition: Continued foreign competition in the consumer segment (China, Taiwan, Korea) and price pressure from hospital buying groups in the medical segment.
• Legal: Various lawsuits are pending, though management does not expect a material adverse impact.

Investor Verification Checklist

• Restructuring Execution: Verify the timeline and cost savings associated with the Bridgeport to Fremont plant relocation.
• Inventory Recovery: Monitor the actual cash recovery from the inventory reduction program against the $2.8 million target for 1996.
• Debt Covenants: Confirm continued compliance with the renegotiated revolving credit facility terms (asset-based formula).
• European Turnaround: Assess the progress of cost-cutting and restructuring in German and English operations to ensure losses are reduced as planned.
• Medical Segment Mix: Evaluate the impact of hospital buying groups on pricing and margins for the medical division.